Cowin Biotech released its first-quarter performance, with a net loss attributable to the parent company of 22.7434 million yuan, narrowing the loss
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Cowin Biotech released its first-quarter report for 2025. The company's first-quarter operating revenue was 43.0055 million yuan, a year-on-year increase of 49.31%; the net loss attributable to shareholders of the listed company was 22.7434 million yuan, a narrowed loss; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 28.7706 million yuan, a narrowed loss; the basic loss per share was 0.21 yuan/share
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments